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Gait Speed and Mood, Cognition, and Quality of Life in Older Adults
With Atrial Fibrillation
Francesca R. Marino, BS; Darleen M. Lessard, MS; Jane S. Saczynski, PhD; David D. McManus, MD, ScM; Luke G. Silverman-Lloyd, BA;
Christopher M. Benson, BS; Michael J. Blaha, MD; Molly E. Waring, PhD
Background-—Low gait speed has been linked with impaired mood, cognition, and quality of life (QOL) in older adults. We examined
whether low gait speed was associated with impaired mood, cognition, and QOL among older adults with atrial fibrillation (AF).
Methods and Results-—Participants (n=1185) had a diagnosis of AF, aged ≥65 years, CHA2DS2VASc ≥2 and had no
contraindications to anticoagulation. Participants completed a 15-foot walk test, and low gait speed was categorized using cutoffs
from the Fried Frailty Index. Participants self-reported measures of depressive symptoms (Patient Health Questionnaire 9 ≥10),
anxiety symptoms (Generalized Anxiety Disorder 7 ≥10), cognitive impairment (Montreal Cognitive Assessment ≤23), and
potentially impaired Atrial Fibrillation Effect Quality-of-Life Questionnaire <80. Participants were on average aged 75.3 (SD: 7.0)
years, 48.0% were women, and 85.5% were non-Hispanic white; 85.6% were taking an oral anticoagulant, 26.1% had low gait speed,
8.4% had elevated depressive symptoms, 5.7% had elevated anxiety symptoms, 41.1% were cognitively impaired, and 41.6% had
potentially impaired AF-related QOL. Participants with low gait speed were significantly more likely to have elevated depressive
symptoms (adjusted odds ratio: 2.1, 95% CI: 1.3–3.4), elevated anxiety symptoms (adjusted odds ratio: 2.2, 95% CI: 1.2–3.9), and
cognitive impairment (adjusted odds ratio: 1.5, 95% CI: 1.1–2.1). Impaired AF-related QOL did not differ by gait speed after
adjustment for clinical characteristics (adjusted odds ratio: 1.1, 95% CI: 0.8–1.5).
Conclusions-—Twenty-six percent of older adults with AF had low gait speed, and low gait speed was associated with impaired
mood and cognition. Further research is needed to determine whether declines in gait speed lead to impaired mood and cognition
or whether these conditions develop concurrently. ( J Am Heart Assoc. 2019;8:e013212. DOI: 10.1161/JAHA.119.013212.)
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A trial fibrillation is the most common sustained arrhyth-mia in older adults and is associated with an increased
risk of stroke. Adults with atrial fibrillation have been found to
have lower quality of life and cardiac performance and higher
rates of cardiac comorbidities such as coronary disease, heart
failure, and hypertension.1,2 Frailty is common among older
adults, and gait speed is one of its predominant compo-
nents.3–5 Atrial fibrillation relates to reduced exercise capac-
ity, cardiac output, frailty, cognition, and vascular function, all
of which may contribute to an observed decrease in gait
speed.6
Gait speed has been used to predict factors such as
depression, anxiety, cognition, and quality of life, which relate
to the functional status of older adults.7–10 Gait speed has
been studied in community-dwelling older adults,7,10 patients
undergoing cardiac surgery,11 and in patients with chronic
stroke, incomplete spinal cord injury, hip fracture, multiple
sclerosis, Parkinson disease, Huntington disease, Alzheimer
disease, and dementia.12 Gait speed is commonly measured
from a walk test, and although there are many published walk
test procedures, the processes are generally simple to
administer and require only a timer and flat surface.10,12
Walk test protocols include either time (eg, 6 minutes) or
distance (eg, 4–10 m)10,12; the Fried Frailty Index includes a
15-foot walk test.3 Published cutoffs for low versus normal
gait speed are also variable, but the most commonly used
cutoffs are between 0.8 and 1 m/s, where gait speeds below
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this range are considered low gait speed.13,14 Using gait
speed as an easy and accurate diagnostic tool could have
meaningful clinical implications.4
Patients experiencing depression or sadness have sig-
nificantly lower gait speeds than those without mood
disorders,15 and this relationship has also been observed in
older adults.16 Gait speed also relates to general anxiety,
balance-, and fall-related anxiety in older adults.9,17 Simi-
larly, those with low gait speed (eg, <0.83 m/s,11 <1.0 m/
s7) are more likely to have morbidity and adverse clinical
outcomes.
While low gait speed has been linked with mood, cognitive
impairment, and quality of life in community-dwelling older
adults and older adults undergoing cardiac surgery, little is
known about the relationship between low gait speed and
these outcomes in older adults with atrial fibrillation, an
important question given that low gait speed is common in
this population.6,7,9,11,15–17 In this study, we examined the
association between low gait speed and elevated depressive
symptoms, elevated symptoms of anxiety, cognition, and
atrial fibrillation-related quality of life in a cohort of older
adults with atrial fibrillation. We hypothesized that patients
with low gait speed will be more likely to have elevated
depressive symptoms, elevated symptoms of anxiety, and
more cognitive impairment, and have lower atrial fibrillation
quality of life as compared with patients with gait speeds in
the normal range.
Methods
Study Design, Participants, and Data Collection
The data that support the findings of this study are available
from SAGE-AF (Systematic Assessment of Geriatric Elements
in Atrial Fibrillation) study principal investigators upon
reasonable request (david.mcmanus@umassmemorial.org
and j.saczynski@northeastern.edu).
Data for the current study are from the SAGE-AF study, an
ongoing prospective cohort study of older adults >65 years
with atrial fibrillation (AF). SAGE-AF enrolled a cohort of 1244
older adults with atrial fibrillation that received care at a
clinical site in Central Massachusetts (University of Massa-
chusetts Memorial Health Care [UMMHC] internal medicine,
UMMHC cardiology, UMMHC electrophysiology, or Heart
Rhythm Associates of Central MA), Eastern Massachusetts
(Boston University cardiology), or Central Georgia (Family
Health Center or Georgia Arrhythmia Consultants). Potential
participants were screened before their upcoming clinic visit,
and eligible participants received an invitation to participate 1
week before this appointment. Eligibility criteria for SAGE-AF
included having a scheduled ambulatory care visit at 1 of the
study practices; having AF (participants were considered to
have a history of AF if the arrhythmia was present on an ECG
or Holter monitor or if AF was noted in any clinic note or
hospital record); being aged ≥65 years; having a CHA2DS2-
VASC risk score ≥2. Participants were not eligible for
enrollment if they had documentation of an absolute
contraindication to oral anticoagulants (ie, large esophageal
varices, recent major surgery within the past 72 hours, recent
major bleeding in the past 3 months, arteriovenous malfor-
mation or aneurysm, planned invasive procedure with high
risk for uncontrollable bleeding [eg, open surgical procedure],
decompensated liver disease, significant thrombocytopenia
[ie, platelet count <50k], or documented hypersensitivity/
allergic reaction to oral anticoagulation); had an indication for
oral anticoagulants other than AF (ie, mechanical heart valve
in the mitral position); did not demonstrate capacity to
provide informed consent as assessed by a capacity instru-
ment that combines direct questions about their understand-
ing of study participation with interviewer observations of the
patient18; did not speak English; had a planned invasive
procedure with high risk for uncontrollable bleeding; were
pregnant; were prisoners; were unwilling or unable to
participate in planned 1- and 2-year follow-up visits at their
study sites. Data were collected through a comprehensive
baseline geriatric assessment, structured interview, and
abstraction of electronic medical records. All participants
provided written informed consent. SAGE-AF was approved by
the Institutional Review Boards at each study site.
At baseline, participants completed a 60-minute in-person
assessment visit that included physical examination and a
survey completed via paper or iPad. Trained research staff
abstracted clinical, demographic, treatment, and laboratory
characteristics from participants’ electronic medical records.
Assessment of Gait Speed
At baseline, participants completed a self-paced 15-foot walk
test following the procedures of the Fried Frailty Index3 as
Clinical Perspective
What Is New?
• We found that 26% of older adults with atrial fibrillation had
low gait speed.
• Low gait speed was associated with elevated symptoms of
depression and anxiety and cognitive impairment.
What Are the Clinical Implications?
• Older adults with atrial fibrillation who are identified as
having low gait speed may benefit from screening for
depression, anxiety, or cognitive impairment and referrals
for mental health care.
DOI: 10.1161/JAHA.119.013212 Journal of the American Heart Association 2
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part of the comprehensive assessment of geriatric elements.
Staff instructed participants to stop at the beginning of a
hallway located in an indoor, private research center, and the
hallway was marked to indicate where participants should
start and stop the 15-foot walk. Study staff were available
throughout the test to provide balance or gait support as
needed. Staff timed the walk test and calculated gait speed.
Gait speed was dichotomized (low versus normal) according
to cutoffs for low gait speed in the Fried Frailty Index.3 This
score stratifies walk time by sex and height, such that men
with a height ≤173 cm had low gait speed if their time to walk
15 feet (walk time) was ≥7 seconds, men with a height
>173 cm had low gait speed if their walk time was
≥6 seconds, women with a height ≤159 cm had low gait
speed if their walk time was ≥7 seconds, and women with a
height >159 cm had low gait speed if their walk time was
≥6 seconds.3 These cutoffs are equivalent to paces of
0.76 m/s (6 seconds) and 0.65 m/s (7 seconds). We con-
ducted a sensitivity analysis in which we categorized low gait
speed as a walking pace of <0.83 m/s for all participants, an
alternative cutoff for slow gait speed also commonly used in
the literature.14
Outcome Measures
As part of the baseline interview, participants completed
measures of depressive symptoms, symptoms of anxiety,
cognitive impairment, and atrial fibrillation quality of life.
Depressive symptoms were assessed using the Patient Health
Questionnaire-9. This 9-item questionnaire asks participants
to self-report the frequency with which they have experienced
depressive symptoms over the past 2 weeks. Response
options for this questionnaire include “not at all,” “several
days,” “more than half the days,” or “nearly every day.”
Symptoms of depression were calculated from the sum of
responses, with a potential range of 0 to 27 (higher scores
indicate more severe depressive symptoms).19 We used a
cutoff of ≥10 to indicate moderate/severe depression.19
Symptoms of anxiety were assessed using the Generalized
Anxiety Disorder-7 Scale. This 7-item scale asks participants
to self-report the frequency with which they have experienced
symptoms of anxiety over the past 2 weeks. Response
options for this scale include “not at all,” “several days,”
“over half the days,” or “nearly every day.” Symptoms of
anxiety were calculated from the sum of responses, with a
potential range of 0 to 21 (higher scores indicate more severe
symptoms of anxiety). We used a cutoff of ≥10 to indicate
moderate/severe anxiety.20
Cognitive impairment was assessed using the Montreal
Cognitive Assessment Battery.21 This 30-item battery includes
an assessment of participants’ visuospatial/executive skills,
naming skills, memory, attention, language, abstraction skills,
delayed recall, and orientation. Cognitive impairment was
calculated from the sum of correct responses, with a potential
range of 0 to 30 (higher scores indicate better cognitive
functioning). We used a cutoff of ≤23 to indicate cognitive
impairment.22
Atrial fibrillation quality of life was assessed using the Atrial
Fibrillation Effect Quality-of-Life (AFEQT) Questionnaire.23 This
20-item questionnaire asks participants to self-report the
extent to which atrial fibrillation has affected their quality of life
in the past month, and there are individual subscales for
symptoms, daily activities, and treatment concern. Response
options for this questionnaire include “not at all bothered OR I
did not have this symptom,” “hardly bothered,” “a little
bothered,” “moderately bothered,” “quite a bit bothered,”
“very bothered,” or “extremely bothered.” Atrial fibrillation
quality of life was calculated according to the following formula:
100[(sum of severity for all questions answered)(number of
questions answered)9100]/[(total number questions
answered)96],24 with a potential range of 0 to 100 (higher
scores indicate better quality of life). We categorized atrial
fibrillation-related quality of life as potentially impaired (<80)
versus not impaired (≥80). A score of 80 indicates that on
average patients responded that they were not at all or hardly
bothered (or not/hardly limited, or experienced no/hardly any
difficulty) by the symptoms, daily activities, and treatment
concerns queried on the AFEQT, and roughly equals the mean
AFEQT scores in patients with atrial fibrillation who maintained
sinus rhythm 3 months after ablation.25 We also examined
atrial fibrillation quality of life as a continuous variable, with
lower scores representing worse atrial fibrillation quality of life.
Potential Confounders
Participants reported their race/ethnicity, education level,
marital status, living situation, number of falls in the past 6
months, and use of a walking aid during the baseline
interview. Age, sex, type of atrial fibrillation, current medica-
tions (eg, oral anticoagulants, beta blockers, calcium channel
blockers), and medical history (eg, type 2 diabetes mellitus,
heart failure, chronic obstructive pulmonary disease) were
abstracted from participants’ medical records.
Statistical Analysis
First, we reported descriptive statistics by gait speed. We
presented frequency and percentages for categorical vari-
ables. We used chi-squared tests to assess differences among
demographic and clinical characteristics by gait speed. Then,
we estimated crude and adjusted odds ratios (ORs) and 95%
CIs for elevated depressive symptoms, elevated symptoms of
anxiety, cognitive impairment, and potentially impaired atrial
fibrillation-related quality of life in relationship to gait speed
DOI: 10.1161/JAHA.119.013212 Journal of the American Heart Association 3
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(low versus normal) using logistic regression models. Demo-
graphic and clinical characteristics that differed by gait speed
were included in adjusted models. We present models
adjusted for demographic characteristics and also models
adjusted for demographic and clinical characteristics. We
additionally included study site (Massachusetts versus Geor-
gia) in adjusted regression models to control for additional
confounding by other differences between sites. We also
examined continuous AF quality of life scores in relationship
to gait speed using linear regression models and the model-
building strategy outlined above. Finally, we conducted a
sensitivity analysis using an alternative definition of low gait
speed (<0.83 m/s).14 P<0.05 was considered statistically
significant. All statistical analyses were conducted using SAS
software version 9.4 (SAS Institute Inc, Cary, NC).
Results
Of the 1244 older adults with atrial fibrillation enrolled in
SAGE-AF, we excluded participants who did not complete the
walk test (n=41). Of the 1203 participants with information on
gait speed, we excluded participants missing information
about any of the variables used in the analysis (n=1 race/
ethnicity, n=18 education), resulting in an analytic sample of
1185 older adults with AF.
Participants were on average 75.3 (SD: 7.0) years old,
48.0% women, 85.5% non-Hispanic white (Table 1). Most
patients (59.6%) had paroxysmal AF, 25.0% had persistent AF,
and 5.7% had permanent AF. The majority (85.6%) were taking
an oral anticoagulant. A quarter (26.1%; n=309) had low gait
speed. Characteristics of the sample in relationship to gait
speed are shown in Table 1.
Overall, 8.4% of participants had elevated depressive
symptoms, 5.7% had elevated anxiety symptoms, and 41.1%
were cognitively impaired. Average atrial fibrillation-related
quality of life was 80.2 (SD: 17.9), and 41.6% had potentially
impaired atrial fibrillation-related quality of life.
Participants with low gait speed were more likely to have
elevated depressive symptoms (16.5% versus 5.6%; adjusted
OR: 2.1, 95% CI: 1.3–3.4), elevated anxiety symptoms (10.7%
versus 3.9%; adjusted OR: 2.2, 95% CI: 1.2–3.9), cognitive
impairment (59.9% versus 34.5%; adjusted OR: 1.5, 95% CI:
1.1–2.1; Figure and Table 2). While potentially impaired atrial
fibrillation-related quality of life differed by gait speed in crude
models and after adjustment for demographics (50.3% versus
35.5%; crude OR: 1.6; 95% CI: 1.2–2.1; adjusted OR: 1.4, 95%
CI: 1.1–1.9; Figure and Table 2), the proportion of patients
with impaired atrial fibrillation-related quality of life did not
differ by gait speed after adjusting for clinical characteristics
(adjusted OR: 1.1; 95% CI: 0.8–1.5; Table 2).
Participants with low gait speed had lower atrial fibrillation-
related quality of life on average than participants without low
gait speed in the crude and adjusted models (M [SD]: 75.6
[20.5] versus 81.9 [16.6]; crude b: 6.3, 95% CI: 8.6 to
4.0, P<0.0001; demographics-adjusted b: 5.2, 95% CI:
7.6 to 2.8, P<0.0001; fully-adjusted b: 3.4, 95% CI:
5.9 to 0.9, P=0.0073). Results from regression models
that included study site as a covariate were nearly identical to
the main findings, and outcomes did not differ by study site
(data not shown). We conducted a sensitivity analysis using an
alternate definition of low gait speed. Using this definition,
41.1% of the sample had low gait speed. Results examining
elevated depressive symptoms, elevated anxiety symptoms,
and cognitive impairment were similar to the main analysis
(data not shown). However, patients with low gait speed were
more likely to have impaired atrial fibrillation-related quality of
life than patients with normal gait speed after adjustment for
demographic and clinical characteristics (adjusted OR: 1.3;
95% CI: 1.0–1.7, P=0.0463).
Discussion
In this study, a quarter of older adults with atrial fibrillation
had low gait speed. Patients with low gait speed had
significantly greater odds of having symptoms of depression,
symptoms of anxiety, cognitive impairment, and potentially
impaired atrial fibrillation-related quality of life, in support of
our hypotheses.
Our findings that patients with AF who have low gait speed
were more likely to have elevated depressive symptoms is
consistent with previous research.8,15,16 Depression is com-
mon among older adults, due in part to the increased
functional decline and social isolation in this population.8,26
While the direction of this relationship is unknown, our
findings suggest there is a strong association between gait
speed and symptoms of depression. Although there are many
factors that can cause depression, studies have shown that
clinically depressed individuals have distinct gait patterns,
posture, and walking speed.15 Furthermore, gait is regulated
by psychomotor skills, which are adversely affected by
depression.27 These skills combine both physical and mental
domains; therefore, it is possible that low gait speed may be
predictive of psychological status.8 Future longitudinal studies
could shed light on whether slowing gait speed leads to an
increase in depressive symptomology, whether the develop-
ment of depression results in lowered gait speed, or whether
low gait speed and depression develop simultaneously.
We also found that patients with low gait speed were more
likely to have elevated anxiety symptoms. Clinical anxiety has
been shown to affect attention and working memory, and
these domains are also involved in regulating gait.9,28–30 One
specific cause of anxiety in older adults is fear related to
balance and falls, and studies have shown that increasing this
type of anxiety results in a more cautious, restricted walking
DOI: 10.1161/JAHA.119.013212 Journal of the American Heart Association 4
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Table 1. Demographic and Clinical Characteristics of Older Adults With Atrial Fibrillation, Overall Sample and in Relationship to
Gait Speed, SAGE-AF 2016 to 2018, N (%)
Total Sample
(N=1185) Low Gait Speed (n=309) Normal Gait Speed (n=876) P Value
Age
65 to 74 y 605 (51.1) 105 (34.0) 500 (57.1) <0.0001
75 to 84 y 433 (36.5) 131 (42.4) 302 (34.5)
85 y 147 (12.4) 73 (23.6) 74 (8.5)
Women 569 (48.0) 190 (61.5) 379 (43.3) <0.0001
Non-Hispanic white 1013 (85.5) 229 (74.1) 784 (89.5) <0.0001
Education
High school, GED, or less 97 (8.2) 45 (14.6) 52 (5.9) <0.0001
Some college, trade school 575 (48.5) 181 (58.6) 394 (45.0)
College/some graduate coursework 187 (15.8) 33 (10.7) 154 (17.6)
Graduate degree 326 (27.5) 50 (16.2) 276 (31.5)
Weight status
Underweight 12 (1.0) 4 (1.3) 8 (0.9) 0.0138
Normal weight 223 (18.8) 67 (21.7) 156 (17.8)
Overweight 415 (35.0) 85 (27.5) 330 (37.7)
Obese 535 (45.2) 153 (49.5) 382 (43.6)
Type of atrial fibrillation
Paroxysmal 706 (59.6) 178 (57.6) 528 (60.3) 0.4535
Persistent/long-standing persistent 296 (25.0) 86 (27.8) 210 (24.0)
Permanent 67 (5.6) 19 (6.2) 48 (5.5)
Other/unknown 116 (9.8) 26 (8.4) 90 (10.3)
Medication use
OAC 1014 (85.6) 270 (87.4) 744 (84.9) 0.2926
Beta blocker 754 (63.6) 218 (70.6) 536 (61.2) 0.0033
Calcium channel blocker 369 (31.1) 93 (30.1) 276 (31.5) 0.6454
Type of anticoagulant among OAC users (n=1014)
Warfarin 566 (55.8) 150 (55.6) 416 (55.9) 0.9191
Other anticoagulant 448 (44.2) 120 (44.4) 328 (44.1)
Prior implantable cardiac device 392 (33.1) 153 (49.5) 239 (27.3) <0.0001
Medical history
Anemia 362 (30.6) 123 (39.8) 239 (27.3) <0.0001
Major bleeding 229 (19.3) 78 (25.2) 151 (17.2) 0.0022
Stroke 109 (9.2) 42 (13.6) 67 (7.7) 0.0019
Renal disease 327 (27.6) 114 (36.9) 213 (24.3) <0.0001
Chronic obstructive pulmonary disorder 291 (24.6) 97 (31.4) 194 (22.2) 0.0012
Type 2 diabetes mellitus 322 (27.2) 119 (38.5) 203 (23.2) <0.0001
Myocardial infarction 233 (19.7) 78 (25.2) 155 (17.7) 0.0041
Peripheral vascular disease 164 (13.8) 58 (18.8) 106 (12.1) 0.0035
Heart failure 429 (36.2) 177 (57.3) 252 (28.8) <0.0001
OAC indicates oral anticoagulants, SAGE-AF, Systematic Assessment of Geriatric Elements in Atrial Fibrillation.
DOI: 10.1161/JAHA.119.013212 Journal of the American Heart Association 5
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style.9,26 Similar to our findings related to depressive
symptoms, future longitudinal studies could elucidate the
directionality of the observed association between low gait
speed and elevated anxiety symptoms.
We also found that patients with low gait speed were more
likely to be cognitively impaired. As previously stated, walking
requires attention, executive function, memory, and other
cognitive demands. It is well documented that these domains,
as well as global cognition, can be affected by age.29,30 Like
cognition, there can also be age-related changes in gait, such
as shortened stride length and slower walking speed. One
explanation for our finding is that physical changes in gait,
such as slower walking speed, are related to declines in the
cognitive domains that regulate posture, balance, and other
gait elements.9 Previous research has documented that
neurologic disease can adversely affect gait, and that gait
speed may also be related to worsening of these impair-
ments.26 These results help explain our finding that patients
with low gait speed had significantly greater odds of having
cognitive impairment.
Finally, we found that patients with low gait speed were
more likely to have potentially impaired atrial fibrillation-
related quality of life in crude models and after adjusting for
demographic characteristics. However, after adjusting for
clinical characteristics, impaired atrial fibrillation-related
quality of life did not differ by gait speed, suggesting that
differences in impaired quality of life can be explained by
differences in clinical burden between patients with low
versus normal gait speed. When examining continuous AFEQT
scores, we found that patients with low gait speed had lower
AF-related quality of life in both crude and adjusted models.
To our knowledge, there is little known about the relationship
between gait speed and disease-specific, atrial fibrillation-
related quality of life; however, previous research in other
cardiac populations and among older adults generally has
shown that low gait speed is predictive of frailty, mortality,
hospitalizations, and overall physical function, all of which
relate to quality of life.11,16,31 Longitudinal studies are needed
to examine whether low gait speed leads to impaired atrial
fibrillation-related quality of life, or whether other health
conditions lead to both declines in gait speed and worsening
of quality of life.
There is no standard cutoff in the literature to indicate
impaired atrial fibrillation-related quality of life as measured
by the AFEQT. We defined impaired quality of life as an AFEQT
score <80, a score similar to the mean AFEQT scores of 81.3
in a previous study of patients with atrial fibrillation who
maintained sinus rhythm 3 months after ablation.25 A score
of 80 indicates that on average patients responded that they
were not at all or hardly bothered (or not/hardly limited, or
experienced no/hardly any difficulty) by the symptoms, daily































Low Gait Speed Normal Gait Speed
Figure. Prevalence of elevated depressive symptoms, elevated anxiety symptoms, cognitive impairment,
and impaired quality of life in relationships to gait speed among older adults with atrial fibrillation, SAGE-AF
(Systematic Assessment of Geriatric Elements in Atrial Fibrillation) 2016 to 2018.
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Future studies may wish to use this cutoff to examine which
patients are more likely to report impaired atrial fibrillation-
related quality of life.
A major limitation of this work is the cross-sectional nature
of the data. For this reason, we are unable to determine the
direction of the relationships between gait speed and our
outcomes. There is evidence to suggest that there is a
bidirectional association between depression and low gait
speed. Studies have shown that depression can affect motor
control, gait, and walking speed, and that low gait speed can
also increase depressive symptoms.8,15,16 It is possible that
some patients may have sought treatment with psychother-
apy or pharmacotherapy and, therefore, did not score high on
the depression or anxiety symptom scales. Furthermore,
patients treated with antidepressants may have experienced
weight gain or alterations to neural circuits, which may have
contributed to altered gait speed.15 Future longitudinal
studies may be able to shed light on whether use of
antidepressants or other medications lead to declines in gait
speed. However, the current study’s findings suggest that low
gait speed is often comorbid with elevated depressive
symptoms, elevated anxiety symptoms, cognitive impairment,
and potentially impaired AF-related quality of life.
This work also has strengths. The SAGE-AF cohort is
geographically diverse, and participants were enrolled from
cardiology, primary care, and electrophysiology clinics, result-
ing in a more generalizable sample of older adults with AF.
The inclusive eligibility criteria allowed us to study patients
who may have otherwise been excluded from clinical studies
because of age, comorbidities, or other factors.
Conclusions
In conclusion, this study of older adults with atrial fibrillation
found that low gait speed was associated with elevated
depressive symptoms, elevated anxiety symptoms, and cog-
nitive impairment. A major limitation of the current study is its
cross-sectional nature, especially given previous research that
is inconsistent about the directionality of these associations.
However, gait speed is easy to measure in the clinical setting
and already commonly used as a screening criterion for some
procedures (eg, transcatheter aortic valve replacement).32,33
The current findings suggest that screening for depression,
anxiety, cognitive impairment, or impaired AF-related quality
of life may be prudent in patients with AF identified as having
low gait speed, and appropriate referrals be made for mental
health care. If future prospective studies were to observe that
patients whose gait speed declined subsequently developed
adverse psychological and cognitive outcomes, then screen-
ing for declines in gait speed and either behavioral or physical
activity interventions to prevent declines in gait speed could
potentially have an impact on these outcomes, thus improving
the lives of older adults with atrial fibrillation.
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